SGLT-2 inhibitors decreased the hazard for the primary CV outcome in patients with CKD regardless of the presence of T2DM (HR 0.76; [95% CI 0.72–0.79]; τ2 = 0; I2 = 0%). This evidence concerns the gene SLC5A2 and chronic kidney disease.